Results 41 to 50 of about 2,541 (178)

A Systematic Mapping Review of 525 Randomised Controlled Trials on Pharmacological and Non‐pharmacological Interventions for People Living With Dementia and Their Formal and Informal Carers in Chinese Communities

International Journal of Geriatric Psychiatry, Volume 41, Issue 7, July 2026.
ABSTRACT Objectives Aligned with the World Health Organization's call for enhanced dementia research to inform national strategies, this systematic mapping review identifies critical gaps in the evidence base for Chinese populations. Representing over 20% of people living with dementia globally, this group remains underrepresented in the Western ...
Cheng Shi, Maximilian Salcher‐Konrad, Jacky C. P. Choy, Dara Kiu Yi Leung, Jingxing Song, Adelina Comas‐Herrera, David Mcdaid, Martin Knapp, Gloria Wong   +8 more
wiley   +1 more source

Comparative analysis of tuberculosis treatment costs: drug-resistant vs. drug-sensitive cases in Vietnam

Bulletin of Faculty of Pharmacy Cairo University
This study analyses the economic and clinical implications of treating pulmonary tuberculosis (TB), focusing on direct treatment costs and patient outcomes at Da Nang Hospital for Lung Diseases in Vietnam.
Thi-Kim-Thang Dao, Dao Dinh, Mai-Hien Chuc, Hai-Anh Ha   +3 more
doaj   +1 more source

Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3872-3882, May 2026.
Abstract Objective To comprehensively assess the cost‐utility of icodec, the first once‐weekly basal insulin, at 700 and 1050 U formulations compared with once‐daily basal insulin analogues in Chinese adults with type 2 diabetes within reimbursement context.
Xichen Tong, Chang Xing, Lei Zhang, Luying Zhang   +3 more
wiley   +1 more source

Combination therapy with Tamsulosin plus Dutasteride Versus Tamsulosin in Benign Prostatic Hyperplasia: a Systematic review & Meta-analysis

Journal of Pharmacoeconomics and Pharmaceutical Management, 2023
Background: This study aims to compare combination therapy efficacy and safety with tamsulosin plus dutasteride versus tamsulosin in benign prostatic hyperplasia.
Behnam Amani, Majid Davari, Bahman Amani, Arash Akbarzadeh, Rouhollah Shabestan   +4 more
doaj  

Proposing a Local “Technology Readiness Assessment” Model for Biopharmaceutical Industries of Iran

Journal of Pharmacoeconomics and Pharmaceutical Management, 2021
Background: Reliable assessment of innovative technology readiness is crucial for industrial decision-making. Technology Readiness Assessment (TRA) is an established tool used to qualify technology development and help make investment decisions and ...
Masoud Faramarzi, Javad Noori, Abbas Kebriaeezadeh, Meysam Seyedifar   +3 more
doaj  

Once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes in China: A cost‐utility and budget impact analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2393-2402, March 2026.
Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong, Yawen Zhang, Lei Zhang, Luying Zhang   +3 more
wiley   +1 more source

Pharmacies for the Pharmacists—Ukrainian Fears and Polish Experiences

Scientia Pharmaceutica, 2020
In 2017, a regulation referred to as “pharmacies for the pharmacists” was implemented in Poland, and Ukraine is going to implement a similar act of law.
Tomasz Zaprutko, Bohdan Hromovyk, Roman Lesyk, Lilia Lesyk, Yuliia Kremin, Krzysztof Kus, Dorota Kopciuch, Piotr Ratajczak, Anna Paczkowska, Elżbieta Nowakowska   +9 more
doaj   +1 more source

Catastrophic pharmaceutical expenditure in patients with type 2 diabetes in Iran

International Journal for Equity in Health, 2022
Objectives This study aimed to assess the financial burden of out-of-pocket (OOP) payments to purchase antidiabetic medicines for type 2 patients in Iran. Method The “budget share” and “capacity to pay” approaches were employed to assess the catastrophic
Leila Zarei, Najmeh Moradi, Farzad Peiravian, Nazafarin Hatami-Mazinani, Motahareh Mahi-Birjand, Jalal Arabloo, Zaheer-Ud-Din Babar   +6 more
doaj   +1 more source

A cost minimization analysis of Azelastine/Fluticasone combination nasal spray versus Azelastine and Fluticasone nasal sprays monotherapy in moderate to severe allergic rhinitis in Iran

Journal of Pharmacoeconomics and Pharmaceutical Management, 2018
Background: Allergic Rhinitis (AR) is a symptomatic disorder which is due to allergen exposure and IgE inflammatory pathway activation in respiratory tract.
Nayyereh Ayati, Delara Babaie, Shekoufeh Nikfar, Erfan Rohani, Marzieh Nosrati, Pardis Zaboli   +5 more
doaj  

Cost–benefit analysis of universal screening for HCV infection in China: a Markov modelling study

BMC Health Services Research
Background Hepatitis C virus (HCV) infection remains a major public health concern in China, contributing substantially to global HCV-related morbidity and mortality.
Dachuang Zhou, Liangxiu Xu, Yimei Zhong, Zhehong Xu, Jun Wang, Yuntian Wang, Yiyang Gao, Jing Xie, Yuting Xia, Wenxi Tang   +9 more
doaj   +1 more source